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Abstract 
Background: Plasma extracellular vesicles (EVs), especially exosome-like vesicles (ELVs), are being increasingly 
explored as a source of potential noninvasive disease biomarkers. The discovery of blood-based biomarkers associ-
ated with ELVs requires methods that isolate high yields of these EVs without significant contamination with highly 
abundant plasma proteins and lipoproteins. The rising interest in blood-based EV-associated biomarkers has led to the 
rapid development of novel EV isolation methods. However, the field suffers from a lack of standardization and often, 
new techniques are used without critical evaluation. Size exclusion chromatography (SEC) has become the method 
of choice for rapid isolation of relatively pure EVs from plasma, yet it has technical limitations for certain downstream 
applications. The recently released exoEasy kit (Qiagen) is a new membrane affinity spin column method for the isola-
tion of highly pure EVs from biofluids with the potential to overcome most of the limitations of SEC.
Methods: By using multiple complementary techniques we assessed the performance of the exoEasy kit in isolating 
ELVs from 2 ml of human plasma and compared it with the SEC qEV column (Izon Science).
Results: Our data show that exoEasy kit isolates a heterogenous mixture of particles with a larger median diameter, 
broader size range and a higher yield than the SEC qEV column. The exclusive presence of small RNAs in the particles 
and the total RNA yield were comparable to the SEC qEV column. Despite being less prone to low density lipoprotein 
contamination than the SEC qEV column, the overall purity of exoEasy kit EV preparations was suboptimal. The low 
particle-protein ratio, significant amount of albumin, very low levels of exosome-associated proteins and propensity 
to triglyceride-rich lipoprotein contamination suggest isolation of mainly non-ELVs and co-isolation of plasma pro-
teins and certain lipoproteins by the exoEasy kit.
Conclusions: We demonstrate that performance of exoEasy kit for the isolation of ELVs for biomarker discovery is 
inferior to the SEC qEV column. This comprehensive evaluation of a novel EV isolation method contributes to the 
acceleration of the discovery of EV-associated biomarkers and the development of EV-based diagnostics.
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Background
The identification of extracellular vesicle (EV)-associated 
biomarkers is crucially dependent on methods that allow 
the isolation of EVs without contaminating plasma pro-
teins and lipoproteins, yield a sufficient quantity of EVs 
for downstream molecular analysis, and are reproducible, 
efficient and easy to perform.
Isolation of EVs from plasma is prone to encounter sev-
eral obstacles related to high plasma viscosity, high lipid 
and protein content and the presence of platelets. Fre-
quently, the sample size is a limiting factor too. Currently, 
standardized protocols for isolation of EVs from plasma 
are missing.
The most popular method for EV isolation, differen-
tial ultracentrifugation, suffers from several limitations 
(impurities, EV aggregation, decreased integrity of EVs) 
and impracticalities (long turnaround time, specialized 
equipment) [1, 2]. The growing interest in blood-based 
EV-associated biomarkers in recent years has led to the 
development of novel EV isolation methods that could 
be well suited for clinical research. Despite the growing 
number of these methods, the field suffers from a lack of 
standardization and often, new techniques are used with-
out detailed comparative analysis.
Size exclusion chromatography (SEC) has been shown 
to perform well in separating EVs from contaminating 
plasma proteins and high density lipoproteins (HDL) [1, 
3, 4] and has been successfully used for small scale analy-
sis of EVs from clinical samples [4, 5]. Despite becoming 
the method of choice for isolation of relatively uncontam-
inated EVs from plasma, SEC has several technical and 
practical limitations. SEC only permits efficient isolation 
of EVs larger than the pore size of the matrix used (i.e. 
70 nm for CL-2B Sepharose). Although free of HDLs, EV-
rich fractions can still contain a small amount of other 
lipoproteins such as chylomicrons (100–600  nm) and 
very low density lipoproteins [VLDL (30–80  nm)] [4, 6, 
7]. Although the sample processing time is short (20 min) 
compared to differential ultracentrifugation, SEC still 
requires considerable hands-on time for the prepara-
tion of the isolation column (if homemade), washing and 
(re)equilibration. In addition, manual collection of frac-
tions may introduce operator-based variability, especially 
affecting the purity of the fractions. Other limitations of 
SEC include the relatively low vesicle yield and the dilu-
tion of a purified sample which requires an additional 
concentrating step that may result in a yield drop [3].
Recently, a new membrane affinity spin column 
method for the isolation of highly pure EVs from bio-
fluids was released (exoEasy kit from Qiagen) [8] that 
appears to have the potential to overcome many of the 
limitations of SEC. In addition, EV isolation can easily 
be coupled with RNA extraction directly from the EVs 
bound to the column membrane (exoRNeasy Serum/
Plasma kit), hence offering a simplified workflow for 
downstream analysis of the RNA content of EVs, which 
could facilitate clinical research into novel EV-associated 
RNA biomarkers.
Here we have compared the large sample volume ver-
sion of the exoEasy kit, the exoEasy Maxi kit, with the 
SEC using qEV 10  ml columns (Izon Science) for isola-
tion of EVs from 2 ml of human plasma. We have focused 
our analysis particularly on ELVs, the clinically most rel-
evant EV subset. We have evaluated the yield, size dis-
tribution and purity of isolated EVs as well as their RNA 
content including size range and yield.
Our data show that the exoEasy kit isolates a heteroge-
neous mixture of particles with a larger median diameter, 
broader size range and a higher yield than the SEC qEV 
column. The exclusive presence of small RNA in the par-
ticles and the total RNA yield were comparable between 
the kits. Despite being less prone to low density lipopro-
tein (LDL) contamination than the SEC qEV column, the 
low particle-protein ratio, significant amount of albumin, 
very low levels of exosome-associated proteins and pro-
pensity to triglyceride-rich lipoprotein contamination 
suggest isolation of mainly non- ELVs and co-isolation of 
plasma proteins and certain lipoproteins by the exoEasy 
kit.
Methods
Sample collection and preparation of platelet‑free plasma 
(PFP)
Two groups of six healthy anonymous donors and three 
lymphoma patients were included in the study. Blood was 
drawn from non-fasting donors into  K2 EDTA tubes (BD 
Vacutainer) and processed within 2  h of blood draw. It 
was centrifuged at 2500×g for 15 min at 20 °C. Cell-free, 
platelet poor plasma was collected and subjected to the 
second centrifugation under the same conditions. The 
supernatant was finally centrifuged at 13,000×g for 5 min 
and the resulting PFP was filtered through a 0.22  µm 
filter, aliquoted and stored at −  80  °C [9]. Prior to use, 
plasma was quickly thawed in a water bath at 37 °C and 
clarified by centrifugation at 10,000×g for 20  min to 
remove apoptotic bodies and microvesicles. The first set 
of six plasma samples from healthy donors was processed 
as described above. For the second set of plasma samples, 
collected from additional six healthy donors and three 
lymphoma patients and used primarily for determination 
of total lipid levels of plasma EVs, plasma ultrafiltration 
and high-speed centrifugation were omitted.
EV isolation from plasma using SEC qEV columns
After rinsing the columns with PBS, 2  ml of PFP were 
applied on top of a qEV column (Izon Science) and 0.5 ml 
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fractions were collected. Four EV-rich fractions (7–10) 
were pooled and either analyzed directly (see below) or 
concentrated using an Amicon Ultra-4 10 kDa centrifugal 
filter device (Merck Millipore).
EV isolation from plasma using exoEasy kit (Qiagen)
This was performed from 2  ml of PFP according to the 
manufacturer’s protocol with modifications described in 
Enderle et al. [8]. EV eluates were either analyzed directly 
(see below) or concentrated as described above. EV elu-
ates from both the SEC qEV columns and the exoEasy kit 
were aliquoted in low protein binding tubes and single 
use aliquots were stored at − 80 °C.
Total protein quantification and Western blot analysis
Proteins were extracted from concentrated pooled EV-
rich SEC qEV fractions or exoEasy kit eluates using a lysis 
buffer (1% NP40, 1 mM EDTA) with a protease inhibitor 
cocktail (Roche). Samples were vortexed and lysed on ice 
for 15  min. The total protein content of EVs was meas-
ured by Pierce BCA Protein Assay Kit (Thermo Scien-
tific). To assess the purity of EV preparations, a ratio of 
number of particles to micrograms of protein was calcu-
lated [10]. The presence of EV-enriched proteins as well 
as the absence of endoplasmatic reticulum (ER) markers 
and plasma proteins was determined by Western blotting 
in 10  µg of lysates using the following antibodies: syn-
tenin-1 (gift from P. Zimmermann), Tsg101 (612697, BD 
Biosciences), CD63 (556019, BD Biosciences), CD81 (sc-
166028, Santa Cruz), calnexin (sc-2679, Santa Cruz) and 
albumin (4929, Cell signaling).
Total lipid quantification
Lipid content of EV preparations was determined by sul-
pho-vanilin assay using the Lipid Quantification Kit (Cell 
Biolabs, San Diego, USA) under conditions optimized for 
EV analysis [6].
Determination of plasma lipoproteins
Levels of plasma triglycerides, total cholesterol, HDL, 
LDL, non-HDL cholesterol, apoA1 and apoB were deter-
mined in a clinical diagnostic laboratory of University 
Hospitals Leuven on a Roche Cobas 8000 chemistry 
analyzer.
Transmission electron microscopy (TEM); negative staining
Aliquots from pooled EV-rich SEC fractions or exoEasy 
kit eluates were deposited onto formvar-coated 400 mesh 
copper grids for 7  min at room temperature and there-
after stained with 1.75% uranyl acetate. The grids were 
observed using a transmission electron microscope JEM 
1400 (Jeol Ltd.).
Nanoparticle Tracking Analysis (NTA)
This was performed using a NanoSight LM10 instrument 
(Malvern Instruments Ltd.). Aliquots from pooled EV-rich 
SEC fractions or exoEasy kit eluates were diluted in filtered 
PBS. Six videos of 30 s were captured for each sample.
RNA isolation from EVs
Total RNA was isolated from concentrated pooled EV-
rich SEC fractions or directly from exoEasy kit columns 
following the protocol of the exoRNeasy Serum/Plasma 
Kit (Qiagen). The protocol was optimized to increase the 
yield by addition of glycogen (5 µg/ml), double extraction 
of the aqueous phase [11] and double elution of RNA. 
RNA yield and size range were analyzed on an Agilent 
2100 Bioanalyzer using the RNA 6000 Pico Kit and the 
Small RNA Kit (Agilent Technologies).
Statistical analysis
Data were analyzed with the GraphPad Prism software 
using Wilcoxon matched-pairs signed rank test with 
p values *  <  0.05 and **  <  0.01. Data are presented as 
mean ± SEM.
Results
ExoEasy kit isolates a highly heterogeneous mix 
of particles from plasma including EVs, proteins 
and lipoproteins
The TEM analysis of pooled fractions 7–10 from the SEC 
qEV columns showed enrichment of exosome-like parti-
cles with a round or cup-shaped appearance, typical for 
this type of EM analysis (Fig. 1a). Apart from ELVs that 
can range in size from 30 to 150  nm, we also observed 
smaller plasma lipoprotein particles [low density lipopro-
teins (LDL)] with a diameter of around 25 nm that were 
not efficiently removed by the qEV column. Lipoprotein 
contamination of SEC EV preparations has been previ-
ously reported [4].
Plasma EV preparations using the exoEasy kit con-
tained high concentration of particles (proteins and lipo-
proteins) and had to be diluted up to 100 times to enable 
observation of individual particles. We found a highly 
heterogeneous mixture of particles in these eluates, illus-
trated by multiple TEM images (Fig. 1a), with a diameter 
ranging from 23 to 511 nm (a median of 150 nm, Fig. 1b). 
ELVs were observed, but much less frequently than in 
SEC qEV eluates. Small (~  25  nm) particles with round 
morphology, likely lipoproteins, were also present. In 
stark contrast to EVs prepared by the SEC qEV column, 
we also noted a substantial presence of proteins (small 
irregular structures; Fig.  1a). Finally, we observed large 
non-spherical particles with a size exceeding 200  nm. 
These structures were present frequently and consistently 
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in repeated experiments in the samples from all six 
healthy donors of the first group, while they were absent 
from the kit elution buffer. The irregular morphology of 
these particles was suggestive of protein aggregates [12]. 
The identity of these particles is yet unknown.
NTA of EVs isolated by the SEC qEV columns showed 
the presence of particles with a size distribution corre-
sponding to the size range of ELVs; with an average mode 
diameter of 117 nm. Particles isolated using the exoEasy 
kit showed a broader size distribution and the principal 
population was significantly larger; with a mode diameter 
of 210  nm (Fig.  2a, b). These results largely agree with 
those of the TEM analysis confirming that the majority 
of the EVs isolated by affinity spin columns was signifi-
cantly larger than the particles isolated by the SEC qEV 
columns.
The NTA also showed a significantly higher number of 
particles isolated by the exoEasy kit compared to the SEC 
qEV columns (Fig. 2c). This result was expected given the 
affinity of the exoEasy column membrane for all EV types 
and is in line with the broader particle size distribution 
profile detected by NTA. However, we did not observe a 
corresponding increase in the enrichment of exosomal 
markers in exoEasy kit preparations (Fig.  3a) which 
would suggest a non-exosomal origin of the majority of 
the isolated particles.
Suboptimal purity of exoEasy kit EV preparations
We measured the amount of protein present in the EV 
samples to evaluate the purity of the isolated EVs. The 
eluates from the exoEasy kit contained significantly 
higher concentrations of total protein than the pooled 
EV-rich fractions from the SEC qEV columns (Fig.  3b). 
The more than tenfold difference in the protein content 
suggests co-isolation of contaminating plasma proteins 
and/or lipoproteins by exoEasy kit.
To further assess the purity, Western blot analysis was 
performed with equal protein loading which allows to 
directly evaluate the purity of the EV samples by com-
paring the enrichment of proteins regarded as exosomal 
markers and the contamination with ER or plasma pro-
teins (Fig.  3a). A recent in depth proteomic analysis of 
EV content by Kowal et al. has re-evaluated the so-called 
exosomal markers [13]. From the proposed updated set 
of exosome-specific proteins, which include syntenin-1, 
TSG101, ADAM10 and EDH4, we have found syntenin-1 
Fig. 1 TEM analysis of EVs isolated by exoEasy kit and SEC qEV columns. Negative staining using uranyl acetate. a Representative images of EV 
isolated from the same donor. ExoEasy samples were diluted 1/20. Magnification ×5000 and ×10,000; scale bar 500 nm (qEV and right image of 
exoEasy) and 200 nm (left image of exoEasy). b Diameter of isolated particles. A total of 50 particles were analyzed in at least three independent 
images per donor. Particles with diameter of > 20 nm were measured. (mean ± SEM, n = 6; *p < 0.05, Wilcoxon matched-pairs signed rank test)
Fig. 2 Nanoparticle tracking analysis of EVs isolated by exoEasy kit and SEC qEV columns. a Representative size distribution profiles of particles 
isolated from the same donor. Normalized concentration of samples is shown. b Mode diameter of particles and c concentration of particles. 
(mean ± SEM, n = 6; *p < 0.05, **p < 0.01, Wilcoxon matched-pairs signed rank test)
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to be highly enriched in EVs isolated by the SEC qEV col-
umns, while it was almost undetectable in EVs isolated 
by the exoEasy kit. A weak syntenin-1 band was detected 
only after a long exposure of the blots (data not shown). 
TSG101 was enriched in EVs isolated by qEV columns, 
but it was undetectable in EVs isolated by exoEasy kit. 
Kowal et  al. further pointed out that the tetraspanin 
CD63 is expressed, apart from in ELVs, also in apop-
totic bodies and hence is less exosome specific, while 
the expression of CD81 was more restricted, with a sig-
nificantly higher presence in ELVs compared to other EVs 
[13]. Accordingly, we detected an enrichment of CD81 
in EVs isolated from the SEC qEV column but not in 
those isolated from the exoEasy kit. The same result was 
obtained for CD63, with undetectable levels found in EVs 
from the exoEasy kit. Our results further show that EVs 
isolated by both kits are not contaminated with endo-
plasmic reticulum membranes components, as indicated 
by the absence of calnexin. Albumin, the most abundant 
plasma protein, was readily detectable in exoEasy kit EVs, 
with an enrichment over five times higher compared to 
the SEC qEV column EVs. Indeed, residual albumin, 
albeit in lower quantities, was also detected in EVs pre-
pared by the SEC qEV columns, as observed previously 
[14].
Another measure of particle purity, the particle-protein 
ratio [10], was significantly lower for the exoEasy kit than 
for SEC qEV samples, indicating co-isolation of proteins 
in exoEasy kit samples (Fig. 3c). The high protein content, 
the low particle-protein ratio together with the undetect-
able/low levels of exosome markers suggest a contami-
nation of exoEasy EV preparations with non-EV plasma 
proteins and lipoproteins.
Since detailed comparative analysis of lipoproteins in 
EV preparations from the exoEasy kit and the SEC qEV 
column was not feasible, due to limitations in plasma 
sample volume, we opted for an alternative analysis, 
which consisted in determining the total lipid content of 
EV preparations by a sulfophosphovanilin (SPV) assay 
[15]. In this context, the total lipid content reflects not 
only the total content of the EV-derived lipids but also 
the total level of lipoprotein contamination of the EV 
preparations. Analysis of EVs prepared from plasma of 
six healthy donors from the first patient group showed 
low concentrations of total lipids in the SEC qEV prep-
arations, not exceeding 10 ng per ml of plasma. In con-
trast, the EVs isolated by exoEasy kit had significantly 
higher total lipid content, with a mean eightfold differ-
ence compared to the SEC qEV-derived EVs (Fig.  3d). 
This result correlates with the higher protein content of 
exoEasy EVs compared to EVs isolated by the SEC qEV 
column (Fig. 3b) and likely reflects both the presence of 
larger particles as well as the co-isolation of plasma lipo-
proteins by exoEasy kit. As shown in Additional file  1: 
Tsg101
50
37
50
37
20
20
75
75
Syntenin-1
CD63
CD81
CD81
short exposure
Albumin
Calnexin
     CL   UC         qEV     exoEasy
     P3HR-1      plasma
qEV exoEasy
0
1×109
2×109
3×109
4×109
pa
rti
cl
e:
pr
ot
ei
n 
ra
tio *
qEV exoEasy
0
50
100
150
pr
ot
ei
n 
[µ
g/
m
l p
la
sm
a]
*
qEV exoEasy
0
20
40
60
80
lip
id
 [µ
g/
m
l p
la
sm
a] *
qE
V
ex
oE
as
y
qE
V
ex
oE
as
y
qE
V
ex
oE
as
y
0
50
100
150
lip
id
 [µ
g/
m
l p
la
sm
a]   normal  high LDL     high TG
a b c
d e
Fig. 3 Protein analysis of EVs isolated by exoEasy kit and SEC qEV columns. a Western blotting analysis of proteins considered as exosome markers, 
non-exosomal proteins and albumin. As controls, cell lysate (CL) of P3HR-1 lymphoblastoid cell line and plasma ELVs prepared by ultracentrifugation 
(UC; based on protocol described by Thery et al [30]) are shown. Representative donor of six analyzed is shown. b Total protein content. c Particles 
to protein ratio and d total lipid content of EV preparations from an original set of plasma samples from six healthy donors, as described in “Meth-
ods”. (mean ± SEM, n = 6; *p < 0.05, **p < 0.01, Wilcoxon matched-pairs signed rank test). e Total lipid content of EV preparations from a second set 
of plasma samples from six healthy donors and three lymphoma patients, as described in Methods. (mean ± SEM, n = 3)
Page 6 of 9Stranska et al. J Transl Med  (2018) 16:1 
Table S1, concentrations of lipids and lipoproteins in the 
healthy donors’ plasma used for EV isolation were all in 
a normal range [16]. Thus, these data served as reference 
for further assessment of the impact of specific lipopro-
tein classes on the level of lipoprotein contamination 
of EV preps. To accomplish this, we used SPV assay to 
analyze an additional set of three plasma samples with 
high levels of LDLs (derived from healthy donors), three 
samples with high levels of triglycerides (derived from 
three lymphoma patients) along with three samples from 
healthy donors with normal levels of all plasma lipopro-
teins (Additional file  2: Table S2). To assess the specific 
effects of these plasma constituents with a greater sensi-
tivity, plasma was processed without ultrafiltration and 
high-speed centrifugation prior to EV isolation. Analysis 
of EVs isolated from the plasma of three healthy donors 
showed again higher total lipid levels in exoEasy kit EV 
preparations compared to those prepared by SEC qEV 
columns (Fig. 3e). The mean total lipid levels of SEC qEV 
preparations were increased compared to those from 
the first set of healthy donor plasma (Fig. 3d). This result 
correlated with the levels of plasma lipids of these three 
healthy donors, which were elevated (except for triglyc-
erides) albeit within the normal range (Additional file 2: 
Table S2), compared to the first healthy donor group 
(Additional file 1: Table S1). The fact that the total lipid 
levels of the exoEasy kit preparations were not affected 
by the change in lipoprotein levels likely indicates that 
the exoEasy kit is less prone to co-isolation of these lipo-
proteins compared to the SEC qEV column.
High levels of plasma LDLs in the 3 healthy donors ana-
lyzed (Additional file 2: Table S2) did not affect the total 
lipid content of EVs prepared by the exoEasy kit, while it 
resulted in a dramatic increase in the lipid concentrations 
in EV preparations from the SEC qEV columns (Fig. 3e). 
Increased levels of triglycerides in the plasma of 3 lym-
phoma patients (Additional file  2: Table S2) led to an 
increase in the total lipid levels in EVs prepared by both 
the exoEasy kit and the SEC qEV columns. Collectively, 
these results show that the total lipid content of the 
exoEasy kit preparations is higher than that of the SEC 
qEV columns. This might reflect both the capacity of the 
exoEasy kit to isolate wider range of vesicles than the SEC 
qEV columns, as shown in Fig. 2a, as well as the presence 
of lipoproteins in EV preparations. The exoEasy kit does 
not seem to co-isolate LDLs, which are present in high 
levels in SEC qEV preparations. Nevertheless, the purity 
of exoEasy EV preparations seems to be compromised by 
co-eluted triglyceride-rich lipoproteins (Fig. 3e).
exoEasy kit EV preparations contain exclusively small RNAs 
with a yield comparable to SEC
As ELVs are considered an important source of RNA-
based biomarkers, we assessed the total RNA content of 
EVs by Bioanalyzer. We found similar RNA recovery by 
both kits, albeit with a slightly lower yield for the SEC qEV 
columns (Fig. 4a). The low RNA yields detected here, with 
a median of ~ 3.8 ng and a range from 2.8 to 7.1 ng per ml 
of plasma are typical for EVs [17–19] and were reported 
previously for exoEasy kit [8]. The Bioanalyzer profiles 
of isolated RNA showed the presence of small RNAs and 
the virtual absence of rRNA for both methods (Fig.  4b). 
This profile was previously shown to be characteristic for 
ELVs [20, 21] and is consistent with the data from the first 
evaluation of this kit [8]. We also calculated the RNA to 
protein ratio, which was previously found to be higher in 
ELVs than in microvesicles suggesting more RNA associ-
ated with ELVs [20]. This ratio was significantly higher for 
EVs isolated by the SEC qEV columns than for EVs iso-
lated by the exoEasy kit (Fig.  4c) suggesting that poten-
tially more non-ELVs are isolated by the exoEasy kit.
Discussion
The growing interest in molecules carried by EVs as 
potential circulating biomarkers has spurred a lot of 
research and development into the methods for isola-
tion of plasma EVs, especially ELVs. The isolation of a 
high yield of high-purity ELVs from plasma is technically 
Fig. 4 RNA analysis of EVs isolated by exoEasy kit and SEC qEV columns. a RNA concentration. b Representative bioanalyzer profiles of RNA isolated 
from the same donor and analyzed by RNA 6000 Pico Kit; the y-axis shows fluorescence units (FU) and the x-axis the nucleotide length (nt) of the 
RNA. Peaks at 25 nt is an internal standard. c Ratio of total amount of RNA (µg) to total amount of protein (µg). (mean ± SEM, n = 6; *p < 0.05, ns; 
not significant, Wilcoxon matched-pairs signed rank test)
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challenging especially due to its high density and viscos-
ity and the complex composition [different types of vesi-
cles, proteins, ribonucleoproteins (RNP), lipoproteins]. 
The methods and protocols to achieve this goal are thus 
under constant development.
Recently several novel methods have emerged in the 
form of a kit that enable an easy and fast isolation of EVs 
from plasma. Among EV isolation methods potentially 
suitable for an EV biomarker discovery we identified 
exoEasy kit (Qiagen), based on its primary evaluation by 
Enderle et al. [8], to be a potentially promising, faster and 
easier-to-use alternative to SEC, the current method of 
choice. EV isolation by the membrane affinity spin col-
umn of exoEasy kit is based on a universal biochemical 
feature specific to EVs. Other particles, such as plasma 
proteins, lipoproteins or RNP complexes that often con-
taminate EVs prepared by classical methods, should not 
be co-isolated. The broader size range expected for EVs 
isolated by the exoEasy kit compared to the lower parti-
cle size limit of 70 nm for EVs isolated by SEC qEV col-
umns could improve the detection of low abundance 
biomarkers and/or enable detection of small size EV-
based biomarkers. Different column sizes allow the iso-
lation of EVs from plasma volumes ranging from 0.1 to 
4 ml. The option to extract RNA directly from column-
bound EVs (exoRNeasy Serum/Plasma kit) is another 
feature that makes this kit attractive for potential clinical 
use. The time required for the purification of EVs using 
the exoEasy kit (25 min) is largely the same as required 
for the SEC qEV columns without the additional hands-
on time for qEV column washing and re-equilibration. 
ExoEasy kit columns cannot be re-used, but enable pro-
cessing up to 4 ml of plasma. Although plasma volumes 
processed by a 10 ml SEC qEV column vary in literature, 
only 0.5  ml is recommended by the manufacturer. The 
SEC qEV columns however, can be re-used up to five 
times thus enabling processing of up to 2.5 ml of plasma.
In this report we provide a comprehensive assessment of 
the exoEasy kit for the isolation of EVs, particularly ELVs, 
from human plasma, focusing on its comparison to the 
currently very popular SEC qEV columns. We used multi-
ple complementary techniques for this purpose [19, 22].
The results of TEM and NTA analyses indicate that 
exoEasy kit isolation results in a highly concentrated sam-
ple containing a heterogeneous mix of particles that dif-
fer greatly in size and shape. Both analysis methods show 
that the majority of particles isolated by affinity spin col-
umns were significantly larger than particles isolated by 
the SEC qEV columns, with a diameter exceeding the typi-
cal size range of ELVs (30–150 nm) [23]. The difference in 
the EV sizes measured by NTA and TEM were expected 
given that particles are analyzed in a hydrated and desic-
cated state, respectively. The hydrodynamic diameter of 
ELVs was reported to be up to three times larger than the 
geometric one [24]. In line with our data, others also have 
detected the presence of larger particles in eluates from 
exoEasy kit when using TEM and light scattering methods 
as a readout [25]. These larger particles were attributed to 
the kit elution buffer. Our NTA analysis of elution buffer 
however did not confirm these findings.
Previous studies have highlighted the differences in EV 
diameter between patients with classical Hodgkin lym-
phoma and healthy donors [5, 26] with patients display-
ing particles with a smaller diameter. The propensity of 
the exoEasy kit to isolate larger vesicles might lead to a 
suboptimal isolation of the population of small EVs from 
the patients’ plasma and might thus affect the subsequent 
biomarker analysis. Similarly, the SEC qEV column cut-
off is 70 nm and thus it is also likely to inefficiently isolate 
smaller EVs. While here we focused primarily on evalua-
tion of the exoEasy kit’s the capacity to isolate ELVs from 
plasma, the isolation of a broad range of vesicles by the 
exoEasy kit could be useful in certain applications.
A high particle concentration was detected by both 
NTA and TEM in exoEasy eluates, however it was not 
reflected by the number of ELVs observed by TEM. 
Instead, the presence of proteins and large size particles 
was readily detected upon sample dilution. Given that 
NTA does not differentiate between vesicles and non-
vesicular particles/aggregates, the higher particle con-
centrations detected in EV preparations from exoEasy 
kit could reflect the presence of RNP complexes, protein 
aggregates or lipoproteins.
Lipoproteins are a major subcellular particle sub-
set of plasma [27], thus it is not surprising that they are 
frequently found in EV preparations from plasma. The 
presence of contaminating lipoproteins in EVs could 
potentially affect certain downstream molecular analyses 
For example HDLs were identified as circulating miR-
NAs carriers [28] Currently, no stand-alone EV isolation 
method results in a complete removal of plasma lipopro-
teins. SEC efficiently removes contaminating proteins 
(<  1%) and HDLs (<  5%) from plasma EVs [3–5] how-
ever recent reports have shown that lipoproteins, espe-
cially LDLs (~ 25 nm, but also aggregates 100–600 nm) 
might co-isolate in exosomal fractions retrieved from the 
SEC qEV columns [3, 6, 27]. Indeed, we have observed 
small spherical particles in our SEC qEV preparations 
with a diameter corresponding to that of LDL. In addi-
tion, we obtained evidence for co-isolation of LDLs and 
triglyceride-rich lipoproteins (chylomicrons, VLDL and 
their remnants) in SEC EV preparations based on the 
total lipid analysis of EVs from plasma of subjects with 
distorted plasma lipoprotein profiles. It is assumed 
that lipoproteins do not co-isolate with EVs during 
exoEasy kit-based EV isolation [8], however this was not 
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previously excluded. Here we demonstrate that exoEasy 
kit is more effective in removing contaminating plasma 
LDLs from EV preparations than the SEC qEV columns, 
while still showing propensity to contamination with tri-
glyceride-rich lipoproteins. Since our other observations 
including the presence of vesicles in the size range of 
VLDLs, a high protein content and a low particle-protein 
ratio could serve as additional indirect evidence for the 
presence of co-isolated lipoproteins, further evaluation of 
co-isolation of other lipoprotein classes is warranted.
In a previously published evaluation of the exoEasy kit 
only a single vesicle marker was used to detect the pres-
ence of EVs [8] and the purity of the EV preparations was 
not assessed. In addition, the manufacturer’s recommen-
dation to concentrate the isolated EVs using a protein filter 
with ≤ 100 kDa pore size may mask the presence of con-
taminating plasma proteins. Focusing our protein analysis 
on a recently updated set of proteins characteristic of ELVs 
we confirmed the high enrichment of these markers, includ-
ing syntenin-1, TSG101, and CD81 in samples from SEC 
qEV columns. In a stark contrast, however, these proteins 
were either undetectable or present only at very low levels 
in exoEasy kit samples. The presence of albumin indicates 
an insufficient purity of the EV preparation, as albumin has 
been shown not to be part of the EV proteome [29]. Albu-
min co-isolated with EVs from exoEasy kit samples at much 
higher levels compared to SEC and together with the low 
particle to protein ratio was another indicator of inferior 
purity of exoEasy kit EVs. We and others have detected low 
levels of albumin in vesicle-rich fractions eluted from SEC 
qEV columns [14]. We should point out that the pool of 
fractions 7–10 was used in this analysis. Using a pool lim-
ited to fractions 7–8/9 results in lower levels of contaminat-
ing albumin (manufacturer’s instructions). qEV columns 
contain the CL-2B Sepharose. Recently other matrices 
(Sepharose CL-4B or Sephacryl S-400) were shown to per-
form better in the separation of EVs from albumin [14].
Conclusions
Here we demonstrate that the performance of the mem-
brane affinity-based exoEasy kit is inferior to the SEC in 
isolating ELVs from human plasma at a quality required 
for identification of ELV-associated biomarkers. This 
study contributes to the rapidly growing EV biomarker 
field for which critical evaluation of novel EV isolation 
methods is essential.
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